Nexien BioPharma, Inc.
Nexien BioPharma, Inc.
Your view on NXEN
Overview
What the company does, where it operates, and who runs it.
About Nexien BioPharma, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Richard S. Greenberg
- Headquarters
- 4340 East Kentucky Avenue, Glendale, CO, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Richard S. Greenberg
- Headquarters
- 4340 East Kentucky Avenue, Glendale, CO, US
Nexien BioPharma, Inc. operates as a pharmaceutical company. It focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, and pre-clinical and clinical pathways for the treatment of various diseases, medical conditions, and disorders.
The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Nexien BioPharma, Inc., and the rating behind it. NXEN last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Nexien BioPharma, Inc.. Starting points for Nexien BioPharma, Inc.: beta -1.14 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Nexien BioPharma, Inc.. Nexien BioPharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Nexien BioPharma, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Nexien BioPharma, Inc.. Nexien BioPharma, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Nexien BioPharma, Inc. valued side by side against its closest peers. Nexien BioPharma, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Nexien BioPharma, Inc., and how their positions are changing. At a $7,077 market value, institutional positions materially move Nexien BioPharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Nexien BioPharma, Inc. executives and directors. Shares of Nexien BioPharma, Inc. have traded between $0.0001 and $0.01 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Nexien BioPharma, Inc.. Nexien BioPharma, Inc. is a $7,077 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Nexien BioPharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Nexien BioPharma, Inc.. Coverage tracks Nexien BioPharma, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.